Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ezgi A. Güleç"'
Autor:
Selin Gerekçi, Ali Deniz Dalgic, Yagmur Caliskan, Can Ozen, Ezgi A. Güleç, Dilek Keskin, Aysen Tezcaner
Publikováno v:
International Journal of Pharmaceutics. 557:97-104
Osteosarcoma is the most common cancer in bone. Drug resistance is a challenge of current treatments that needs to be improved with novel treatment strategies. In this research, a new dual drug delivery system was developed with Gemcitabine (GEM) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79c766346ead0ba6767a25dfc3d4ade6
https://doi.org/10.1016/j.ijpharm.2018.12.041
https://doi.org/10.1016/j.ijpharm.2018.12.041
Publikováno v:
Amino Acids. 50:1607-1616
The second mitochondria-derived activator of caspase (Smac/DIABLO) is a pro-apoptotic protein that released from mitochondria into the cytosol when cells undergo apoptosis. Smac promotes caspase activation by binding the inhibitors of apoptosis prote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::975c2b4266574d068c7cceb2da4cda0b
https://doi.org/10.1007/s00726-018-2637-0
https://doi.org/10.1007/s00726-018-2637-0
Autor:
Can Ozen, Hazal Hepsen Husnugil, Ayşenur Biber, Selin Gerekçi, Ipek Zeynep Durusu, Ezgi A. Güleç, Heval Atas
Publikováno v:
Leukemia Research. 55:33-40
Multiple Myeloma (MM) is a malignant neoplasm of bone marrow plasma B cells with high morbidity. Clofazimine (CLF) is an FDA-approved leprostatic, anti-tuberculosis, and anti-inflammatory drug that was previously shown to have growth suppression effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2fd355d86e0b6356e372b7a4303039
https://doi.org/10.1016/j.leukres.2017.01.019
https://doi.org/10.1016/j.leukres.2017.01.019